Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    TopAbstracts in Rheumatoid Arthritis 11/27/2008 - (DGNews)
    TopAbstracts in Rheumatoid Arthritis 11/13/2008 - (DGNews)
    Declining Benefit of Combination Therapy for Rheumatoid Arthritis Found in Long-Term Follow-Up of Patients: Presented at ACR-ARHP - (DGDispatch)
    Genetic Markers Point to Increased Risk of Infection in Patients With Rheumatoid Arthritis: Presented at ACR-ARHP - (DGDispatch)
    Efficacy of Rituximab Is Sustained in Patients With Rheumatoid Arthritis: Presented at ACR-ARHP - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
      B-Cell Biology and B-Cell-Targeted Therapies for Autoimmune Rheumatic Diseases: The Role of the Allied Health Professional
      Advances in B-Cell Biology in the Treatment of Autoimmune and Inflammatory Diseases
      The Management of Difficult Rheumatoid Arthritis
      Expanding the Armamentarium for the Treatment of Juvenile Rheumatoid Arthritis: Update for Managed Care Pharmacists
      Hepatic Effects of Biologic Agents: Current and Future Issues in the Treatment of Rheumatoid Arthritis

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Adalimumab Induced Mononeuritis Multiplex in a Patient with Refractory Rheumatoid Arthritis: A Case Report
        Disseminated Cutaneous Herpes Simplex Virus-1 in a Patient with Rheumatoid Arthritis Receiving Infliximab: A Case Report
        Rheumatoid Nodule of the Thyrohyoid Membrane: A Case Report
        Recurrent Pneumothorax in a Patient with Rheumatoid Arthritis on Leflunomide Treatment: Case Report and Overview of the Literature
        Spontaneous Esophageal Perforation in a Patient with Achalasia Cardia and Rheumatoid Arthritis

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Subcutaneous Methotrexate Offers Superior Bioavailability Compared to Oral Administration in Patients With Rheumatoid Arthritis

        A DGReview of :"Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis"
        Journal of Rheumatology

        06/29/2004
        By Shane Alexander


        Bioavailability of subcutaneously administered methotrexate is superior to orally administered higher dose (>/= 25 mg/week) methotrexate, according to a new study. This could lead to increased efficacy in patients with rheumatoid arthritis

        "Our data suggest that doses between 25 and 40 mg MTX per week, administered orally, result in limited bioavailability," write Monique Hoekstra, MD, Department of Rheumatology, Medisch Spectrum Twente, Enschede, the Netherlands, and colleagues.

        Methotrexate has a dose-effect relationship, although no definite relation between pharmacokinetic parameters and efficacy has been established. It is likely that an improvement in bioavailability will lead to better efficacy, report the investigators.

        Previous pharmacokinetic studies in adult patients with rheumatoid arthritis demonstrated comparable bioavailability of oral and parenteral methotrexate (MTX) in doses up to 25 mg/week. It appeared that at doses above 25 mg/week, parenteral administration offered superior bioavailability though it is not known whether the bioavailability of intravenous (IV), intramuscular (IM) and subcutaneous (SC) methotrexate are strictly comparable.

        In this study, a total of 15 patients treated for more than 3 months with oral or parenteral higher dose ¡Ý 25 mg/week) MTX were recruited. Pharmacokinetic analysis was performed twice, in random order, in each patient with an interval of 2 weeks between analysis. One analysis was performed with regular higher dose oral MTX and another with the same dose of subcutaneously administered MTX.

        Comedication was allowed throughout the study: 3 patients used hydrochloroquine, 1 patient used sulfasalazine, and another aurothiomalate. Eight patients used low-dose (¡Ü 10 mg/day) prednisolone and 11 nonsteroidal anti-inflammatory drugs (NSAID). All patients received folic acid supplementation except on the day MTX was administered.

        The bioavailability of higher dose oral MTX (¡Ý 25 mg/week) varied greatly ( range .21 to .96) with a mean value of 0.64. The area under the curve (AUC) of oral MTX was significantly lower than AUC of subcutaneous MTX (P < .001).

        "The number of patients in our study with different MTX doses was too small to draw conclusions about a dose-bioavailability relation," note the researchers. "However, there is a positive relation between the subcutaneous AUC and the dose of MTX (linear regression; R2 = .33, P = .03), whereas the oral AUC does not increase with an increasing dose."

        "In our opinion, additional controlled trials are needed to evaluate the effect of higher doses of MTX, which are in fact widely used in rheumatology practice," the authors conclude.

        J Rheumatol 2004 Apr;31:4:645-8 "Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send